Oxadiazoles are a class of heterocyclic aromatic compounds with the molecular formula C2H2N2O, which have special biological activities and thermodynamic properties. Five-membered heterocyclic moieties composed of three or two heteroatoms are of great interest to researchers because these compounds show significant therapeutic potential. These heterocycles can serve as a building block for the development of novel molecular structures.
Navacaprant, a novel and selective kappa opioid receptor(KOR) antagonist, has no agonist properties implicated in opioid-related abuse.
Navacaprant is a potent KOR antagonist currently in clinical development for the treatment of neurobehavioral disorders, including Phase 3 clinical trials in adults with major depressive disorder. Navacaprant demonstrates high affinity and selectivity for the human KOR over the human MOR and DOR and exhibits reversible antagonist activity at KOR ex vivo and in vivo.